Published in Br J Pharmacol on January 01, 2005
Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev (2009) 1.90
Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther (2006) 1.19
Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury. Neurotherapeutics (2011) 1.12
A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res Ther (2011) 1.04
Inhibition of interleukin-1beta-induced matrix metalloproteinases 1 and 13 production in human osteoarthritic chondrocytes by prostaglandin D2. Arthritis Rheum (2008) 0.95
Impact of gentamicin-supplemented polyvinylidenfluoride mesh materials on MMP-2 expression and tissue integration in a transgenic mice model. Langenbecks Arch Surg (2010) 0.87
Matrix Metalloproteinases in Non-Neoplastic Disorders. Int J Mol Sci (2016) 0.81
Effect of methotrexate on collagen-induced arthritis assessed by micro-computed tomography and histopathological examination in female rats. Biomol Ther (Seoul) (2015) 0.76
Anti-arthritic activity of Fu-Fang-Lu-Jiao-Shuang on collagen-induced arthritis in Balb/c mice and its underlying mechanisms. Pharmacogn Mag (2015) 0.76
Anti-inflammatory activities of light emitting diode irradiation on collagen-induced arthritis in mice (a secondary publication). Laser Ther (2014) 0.75
Early detection of rheumatoid arthritis in rats and humans with 99mTc-3PRGD2 scintigraphy: imaging synovial neoangiogenesis. Oncotarget (2016) 0.75
Micro-computed tomography evaluation and pathological analyses of female rats with collagen-induced arthritis. J Vet Sci (2015) 0.75
Influence of gentamicin-coded PVDF suture material on the healing of intestinal anastomosis in a rat model. Int J Colorectal Dis (2015) 0.75
Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med (1977) 10.09
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
Immunisation against heterologous type II collagen induces arthritis in mice. Nature (1980) 7.08
Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem (1995) 5.57
Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res (1998) 4.39
Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol (2003) 4.16
Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem (1997) 3.74
Matrix metalloproteinases in tumour invasion and metastasis. J Pathol (1999) 2.65
Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum (2003) 2.57
Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum (1982) 2.35
Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol (1999) 2.34
Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. J Clin Invest (1989) 2.20
Collagen-induced arthritis in rats. Evaluation of early immunologic events. Arthritis Rheum (1979) 2.16
Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum (1998) 2.00
Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest (1997) 1.97
Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum (1994) 1.93
Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem (2003) 1.93
Composition and structure of articular cartilage: a template for tissue repair. Clin Orthop Relat Res (2001) 1.79
IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest (2000) 1.74
An immunoelectron microscope study of the organization of proteoglycan monomer, link protein, and collagen in the matrix of articular cartilage. J Cell Biol (1982) 1.60
Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res (2003) 1.52
MT1-MMP: a tethered collagenase. J Cell Physiol (2004) 1.45
VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis. J Clin Invest (1995) 1.43
Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. J Immunol (2002) 1.40
Complex role of matrix metalloproteinases in angiogenesis. Cell Res (1998) 1.37
Proteinases in bone resorption: obvious and less obvious roles. Clin Chim Acta (2000) 1.33
Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum (1999) 1.32
Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest (1996) 1.29
Joint destruction in arthritis: metalloproteinases in the spotlight. Arthritis Rheum (1991) 1.21
Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark? Arthritis Rheum (2002) 1.14
Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis (2001) 1.13
Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury. Am J Pathol (1996) 1.13
Tissue distribution and clearance of soluble murine TNF receptors in mice. Cytokine (1994) 1.05
Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol (1997) 1.01
Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis--targetting gelatinase A activation. Inflamm Res (2001) 0.96
Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation. Br J Rheumatol (1998) 0.95
Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis. Osteoarthritis Cartilage (1997) 0.95
Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum (1998) 0.94
Animal models of rheumatoid arthritis. Mol Med Today (1999) 0.93
A microplate assay specific for the enzyme aggrecanase. Anal Biochem (2003) 0.85
Matrix metalloproteinases and venous leg ulceration. Eur J Dermatol (2000) 0.83
Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase-inhibitor. Br J Pharmacol (2000) 0.81
How do the biologics fit into the current DMARD armamentarium? J Rheumatol Suppl (2001) 0.81
A factor derived from polymorphonuclear leukocytes enhances interleukin-1-induced synovial cell collagenase and prostaglandin E2 production in rats. Eur J Biochem (1996) 0.79
Comparison of collagenase-cleaved articular cartilage collagen in mice in the naturally occurring STR/ort model of osteoarthritis and in collagen-induced arthritis. Osteoarthritis Cartilage (2002) 0.78
The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies. Rheumatology (Oxford) (1999) 0.77
Prevention of cartilage breakdown by matrix metalloproteinase inhibition--a realistic therapeutic target? Br J Rheumatol (1998) 0.77
Identification of a primary target of thalidomide teratogenicity. Science (2010) 7.09
Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun (2005) 1.65
Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. Eur J Pharmacol (2004) 1.64
Palladium(0)-catalyzed tandem cyclization of allenenes: direct construction of tricyclic heterocycles through aromatic C--H activation. Chemistry (2005) 1.31
Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol Pharm Bull (2004) 1.30
Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol (2002) 1.17
Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds. Microbiol Immunol (2008) 1.11
Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull (2005) 1.04
Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos (2003) 1.03
Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors. FEBS Lett (2005) 0.96
Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol (2003) 0.95
Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol (2003) 0.95
Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull (2005) 0.92
Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. Biochem Pharmacol (2007) 0.91
Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction. Transpl Immunol (2010) 0.91
Tacrolimus (FK506) limits accumulation of granulocytes and platelets and protects against brain damage after transient focal cerebral ischemia in rat. Biol Pharm Bull (2007) 0.91
A highly regio- and stereoselective formation of bicyclo[4.2.0]oct-5-ene derivatives through thermal intramolecular [2 + 2] cycloaddition of allenes. J Org Chem (2007) 0.91
FK506 suppresses E-selectin, ICAM-1 and VCAM-1 expression on vascular endothelial cells by inhibiting tumor necrosis factor alpha secretion from peripheral blood mononuclear cells. Cytokine (2005) 0.91
Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol (2004) 0.90
Role of cyclooxygenase-2, but not cyclooxygenase-1, on type II collagen-induced arthritis in DBA/1J mice. Biochem Pharmacol (2003) 0.89
A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia. J Pharmacol Exp Ther (2004) 0.89
FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. Eur J Pharmacol (2005) 0.89
FK1706, a novel non-immunosuppressive immunophilin: neurotrophic activity and mechanism of action. Eur J Pharmacol (2005) 0.88
Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR217840. Eur J Pharmacol (2005) 0.88
Excitatory amino acid transporters expressed by synovial fibroblasts in rats with collagen-induced arthritis. Biochem Pharmacol (2005) 0.88
Discovery of the first non-peptide full agonists for the human bradykinin B(2) receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks. J Med Chem (2004) 0.87
Efficacy of oral treatment with tacrolimus in the renal transplant model in cynomolgus monkeys. J Pharmacol Sci (2008) 0.86
Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J Rheumatol (2003) 0.86
Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative. Bioorg Med Chem Lett (2005) 0.86
Multiple modes of action of tacrolimus (FK506) for neuroprotective action on ischemic damage after transient focal cerebral ischemia in rats. Brain Res (2004) 0.86
Cartilage destruction in collagen induced arthritis assessed with a new biochemical marker for collagen type II C-telopeptide fragments. J Rheumatol (2004) 0.86
FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator. J Cereb Blood Flow Metab (2005) 0.86
Improving quality and harvest period of protein crystals for structure-based drug design: effects of a gel and a magnetic field on bovine adenosine deaminase crystals. Acta Crystallogr D Biol Crystallogr (2003) 0.85
Temporal and topographic profiles of tissue hypoxia following transient focal cerebral ischemia in rats. J Vet Med Sci (2006) 0.85
Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur J Pharmacol (2007) 0.85
Therapeutic time window of tacrolimus (FK506) in a nonhuman primate stroke model: comparison with tissue plasminogen activator. Exp Neurol (2006) 0.85
A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties. J Pharmacol Exp Ther (2006) 0.84
Antiemetic activity of FK1052, a 5-HT3- and 5-HT4-receptor antagonist, in Suncus murinus and ferrets. J Pharmacol Sci (2005) 0.84
Thermal intramolecular [2+2] cycloaddition of allenenes and allenynes: diastereoselective access to bicyclic nitrogen heterocycles. Angew Chem Int Ed Engl (2005) 0.83
Hyperoxia-induced emphysematous changes in subacute phase of endotoxin-induced lung injury in rats. Am J Physiol Lung Cell Mol Physiol (2004) 0.83
Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Lett (2003) 0.83
Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Pharmacol Exp Ther (2004) 0.83
FK1706, a novel non-immunosuppressant neurophilin ligand, ameliorates motor dysfunction following spinal cord injury through its neuroregenerative action. Eur J Pharmacol (2008) 0.83
FK506 ameliorates spontaneous locomotor activity in collagen-induced arthritis: implication of distinct effect from suppression of inflammation. Int Immunopharmacol (2005) 0.83
Investigation of the electrochemical oxidation products of zotepine and their fragmentation using on-line electrochemistry/electrospray ionization mass spectrometry. J Mass Spectrom (2006) 0.83
Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma. Biol Pharm Bull (2006) 0.83
A new poly(ADP-ribose) polymerase inhibitor, FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice. J Pharmacol Exp Ther (2004) 0.82
Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors. J Pharmacol Sci (2004) 0.82
Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull (2004) 0.82
Effect of a new immunosuppressant histon deacetylase (HDAC) inhibitor FR276457 in a rat cardiac transplant model. Biol Pharm Bull (2008) 0.82
Tacrolimus, a potential neuroprotective agent, ameliorates ischemic brain damage and neurologic deficits after focal cerebral ischemia in nonhuman primates. J Cereb Blood Flow Metab (2003) 0.82
Pharmacological profile of FR260330, a novel orally active inducible nitric oxide synthase inhibitor. Eur J Pharmacol (2005) 0.81
Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis. Br J Pharmacol (2003) 0.81
Enzyme activities of the nitric oxide-cGMP pathway in corpus cavernosum isolated from middle-aged rats. Eur J Pharmacol (2003) 0.81
FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. J Pharmacol Sci (2005) 0.81
FK506 induces chondrogenic differentiation of clonal mouse embryonic carcinoma cells, ATDC5. Eur J Pharmacol (2002) 0.81
Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model. Transpl Immunol (2009) 0.81
Prohemorrhagic and bleeding time activities of recombinant tissue plasminogen activator, heparin, aspirin, and a glycoprotein IIb/IIIa antagonist. J Neurotrauma (2005) 0.81
Purification and characterization of β-mannanase from Reinekea sp. KIT-YO10 with transglycosylation activity. Biosci Biotechnol Biochem (2014) 0.81
Tacrolimus (FK506) suppresses rt-PA-induced hemorrhagic transformation in a rat thrombotic ischemia stroke model. Brain Res (2008) 0.80
Functional characterization of single nucleotide polymorphisms with amino acid substitution in CYP1A2, CYP2A6, and CYP2B6 found in the Japanese population. Drug Metab Pharmacokinet (2004) 0.80
Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells. Int Immunopharmacol (2007) 0.80
Monoclonal antibody 1-22-3-induced glomerulonephritis in uninephrectomized rats as a model of progressive renal failure. Nephrol Dial Transplant (2005) 0.80
Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors. Drug Metab Pharmacokinet (2004) 0.80
Resiniferatoxin antagonizes cisplatin-induced emesis in dogs and ferrets. Eur J Pharmacol (2002) 0.80
A new class of nonpeptide bradykinin B(2) receptor ligand, incorporating a 4-aminoquinoline framework. Identification of a key pharmacophore to determine species difference and agonist/antagonist profile. J Med Chem (2004) 0.80
Selective ligand purification using high-performance affinity beads. Anal Biochem (2005) 0.80
Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. Eur J Pharmacol (2005) 0.80
Tacrolimus (FK506) has protective actions against murine bleomycin-induced acute lung injuries. Eur J Pharmacol (2005) 0.80
Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull (2004) 0.79
Glucose oxidase assisted homogeneous electrochemical receptor binding assay for drug screening. Biosens Bioelectron (2005) 0.79
Identification of natural diterpenes that inhibit bacterial wilt disease in tobacco, tomato and Arabidopsis. Plant Cell Physiol (2012) 0.79
Thirteen-month inhibition of aldose reductase by zenarestat prevents morphological abnormalities in the dorsal root ganglia of streptozotocin-induced diabetic rats. Brain Res (2008) 0.78
Inhibition of antigen-induced airway inflammation and hyperresponsiveness in guinea pigs by a selective antagonist of "chemoattractant receptor homologous molecule expressed on Th2 cells" (CRTH2). Eur J Pharm Sci (2013) 0.78